**DOCKET NO.: PHRM-0303** 

# PATENTO DATE OF THE PATENTS OF THE P

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In	Re	Apr	lica	ition	of:
----	----	-----	------	-------	-----

Mark E. Gurney and Irene Abraham

Patent Application

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: Transgenic Mouse Model of Human Neurodegenerative Disease

EXPRESS MAIL LABEL NO: EL567666576US DATE OF DEPOSIT: January 22, 2001

	Provisional Design
	ant Commissioner for Patents ngton DC 20231
Sir:	
	PATENT APPLICATION TRANSMITTAL LETTER
	Transmitted herewith for filing, please find
×	A Utility Patent Application under 37 C.F.R. 1.53(b).
	It is a continuing application, as follows:
	☐ continuation ☐ divisional ☐ continuation-in-part of prior application number/
	A Provisional Patent Application under 37 C.F.R. 1.53(c).
	A Design Patent Application (submitted in duplicate).
	Request for Nonpublication. The invention(s) disclosed in the present application filed herewith has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication

of applications 18 months after filing. Thus, pursuant to 35 U.S.C. §122(b)(2)(B)(i), Applicant(s) request that the above-identified patent application not be published.

Includ	ing the	followi	ng:			
	Provisional Application Cover Sheet.					
$\boxtimes$	New o	or Revised Specification, including pages to containing:				
	$\boxtimes$	Specif	ication			
	$\boxtimes$	Claim	s			
	$\boxtimes$	Abstra	act			
		Substi	tute Specification, including Claims and Abstract.			
			The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.			
			The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.			
	_, inclinew notes declar	uding S natter haration fo	rlier application Serial No Filed			

	reference.
	Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section): "This Application:  \[ \sum \text{ is a continuation of } \sum \text{ is a divisional of } \sum \text{ claims benefit of U.S.} \]  provisional Application Serial No
	<u> </u>
	Signed Statement attached deleting inventor(s) named in the prior application.
	A Preliminary Amendment.
	2 Sheets of Formal Informal Drawings.
	☐ Drawing view to publish: Figure _1
	Petition to Accept Photographic Drawings.
	☐ Petition Fee
×	An $\square$ Executed $\bowtie$ Unexecuted Declaration or Oath and Power of Attorney.
	An Associate Power of Attorney.
	An   Executed Copy of Executed Assignment of the Invention to
	☐ A Recordation Form Cover Sheet.
	Recordation Fee - \$40.00.
	The prior application is assigned of record to
	Priority is claimed under 35 U.S.C. § 119 of Patent Application No.
	filed in
	(country).
	A Certified Copy of each of the above applications for which priority

	is claimed:  is enclosed.  has been filed in prior application Serial No filed
	An  Executed or  Copy of Executed Earlier Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27  is enclosed.  has been filed in prior application Serial No filed , said status is still proper and desired in present case.
$\boxtimes$	Diskette Containing DNA/Amino Acid Sequence Information.
<b>5</b> 2	
$\boxtimes$	Statement to Support Submission of DNA/Amino Acid Sequence Information.
	The computer readable form in this application, is identical with that filed in Application Serial Number, filed, In accordance with 37 CFR 1.821(e), please use the first-filed, last-filed or only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification.
	Information Disclosure Statement.
	<ul> <li>☐ Attached Form 1449.</li> <li>☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.</li> </ul>
	A copy of Petition for Extension of Time as filed in the prior case.
	Appended Material as follows:
	·
$\boxtimes$	Return Receipt Postcard (should be specifically itemized).

DOCKET N	NO.: PHRM-0303 - 5 -	PATENT
	Other as follows:	
מממ	CALCULATION:	
ree —		. C41
	Cancel in this application original claims	
	before calculating the filing fee. (At least one or	riginal independent claim musi
	be retained for filing purposes.)	

********			SMALL	ENTITY	NOT SMA	LL ENTITY
			RATE	FEE	RATE	FEE
PROVISIONAL A	PPLICATION		\$75.00	\$	\$150.00	\$
DESIGN APPLICA	ATION		\$160.00	\$	\$320.00	\$
UTILITY APPLIC	CATIONS BASE FE	EE	\$355.00	\$	\$710.00	\$710.00
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS						
	No. Filed	No. Extra			<b></b>	*******
	44 - 20 =	24	\$9 each	\$	\$18 each	\$432.00
INDEP. CLAIMS	5 - 3 =	2	\$40 each	\$	\$80 each	\$160.00
TOTAL CLAIMS  INDEP. CLAIMS  5 -3 = 2  FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$135	\$	\$270	\$270.00
ADDITIONAL FILING FEE		<b>*******</b>	\$		\$	
TOTAL FILING FEE DUE			<b>************</b>	\$		\$1,572.00

$\boxtimes$	A Check is enclosed in the amount of \$1,572.00
-------------	---

$\boxtimes$	The Commissioner is authorized to charge payment of the following fees and to
	refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

The	foregoing	amount	due.
 1110	TOTOGOTHE	aniount	uuc.

- Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

- X Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.  $\boxtimes$ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d). The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.
- $\boxtimes$ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: January 22, 2001

Robin S. Ouartin Registration No. 45,028

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 1997 WWKMN

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark E. Gurney and Irene Abraham

Serial No.: Not yet assigned Group Art Unit: Not yet assigned

Filing Date: Herewith Examiner: Not yet assigned

For: Transgenic Mouse Model of Human Neurodegenerative Disease

### **BOX SEQUENCE**

Assistant Commissioner for Patents Washington DC 20231

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

$\boxtimes$	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

**DOCKET NO.: PHRM-0303** 

Date: January 22, 2001

Robin S. Quartin
Registration No. 45,028

- 2 -

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 1997 WWKMN

**PATENT**